Valore202020212022202320242025TTMSpese di vendita, generali e amministrative14.2 B14.89 B14.25 B12.52 B12.57 B13.25 B—Ricerca e sviluppo8.98 B9.54 B10 B11.37 B10.02 B11.2 B—Reddito operativo10.15 B11.69 B9.2 B9.77 B14.54 B17.64 B—Proventi non operativi, Totale———————Oneri finanziari, al netto degli interessi capitalizzati———————Proventi non operativi, esclusi gli oneri finanziari———————Entrate/uscite straordinarie———————Utile al lordo delle imposte9.88 B26.14 B2.38 B596 M3.54 B329 M—Quota di utile———————Imposte1.81 B2.12 B1.42 B551 M1.7 B2.38 B—Interessi di minoranza1 M3 M04 M2 M17 M—Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate3.48 B19.43 B6.96 B8.57 B5.66 B7.68 B—Attività cessate4.59 B4.59 B—6.28 B6.28 B6.28 B—Utile netto8.07 B24.02 B6.96 B14.85 B11.94 B13.97 B—Regolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari———————Utile base per azione (EPS base)———————Utile diluito per azione (EPS diluito)———————Numero medio di azioni ordinarie in circolazione———————Azioni diluite in circolazione———————EBITDA———————EBIT———————Costo del fatturato15.12 B15.87 B15.49 B12.47 B12.83 B13.7 B—Altri costi del venduto———————Ammortamento e svalutazione (liquidità)———————
Novartis AG
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz.